Resmed (RSMDF) Research & Development (2009 - 2026)

Resmed (RSMDF) has reported Research & Development for 18 consecutive years, with $105.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 22.3% year-over-year to $105.7 million; the trailing twelve-month figure through Jun 2026 stood at $378.3 million (up 14.19% YoY), and the FY2026 full-year result was $378.3 million, up 14.19% from the prior year.
• Research & Development advanced to $105.7 million in Q2 2026 per RSMDF's latest filing, from $94.3 million in the prior quarter.
• Across five years, Research & Development topped out at $105.7 million in Q2 2026 and bottomed at $63.2 million in Q3 2022.
• Historically, Research & Development has averaged $79.8 million across 5 years, with a median of $78.8 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Research & Development advanced 0.83% in 2024, then grew 22.3% in 2026.
• Over 5 years, Research & Development stood at $69.9 million in 2022, then climbed by 5.73% to $73.9 million in 2023, then increased by 10.14% to $81.4 million in 2024, then increased by 11.79% to $91.0 million in 2025, then climbed by 16.22% to $105.7 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $105.7 million, $94.3 million, and $91.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.